Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos,

Slides:

Advertisements

Similar presentations

MRI as an Alternative to CT-Guided Biopsy of Adrenal Masses in Patients With Lung Cancer Lawrence H Schwartz, Michelle S Ginsberg, Michael E Burt, Karen.

Advertisements

Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series Kevin C. Keith, Yueh Lee, Matthew G. Ewend, Timothy.

Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment Diego Marquez-Medina, Sanjay Popat

Acrometastasis from an epidermal-growth-factor-receptor (EGFR) mutation-positive lung adenocarcinoma Mau-Ern Poh, Chong-Kin Liam, Jiunn-Liang Tan, Yong-Kek.

Combined small cell lung cancer originated from small pure ground-glass nodule— Long-term observation after computed tomography screening Kentaro Miura,

Medical Imaging Technologies

Rohit Venkatesan, Amir Salam, Issam Alawin, Maurice Willis

Non-Hodgkin's lymphoma presenting as an isolated chest wall tumour

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Erosion of lumbar vertebral bodies from a chronic contained rupture of an abdominal aortic pseudoaneurysm W. Andrew Oldenburg, MD, Tariq Almerey, MD

Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity.

Spontaneous regression of malignant pleural mesothelioma: A case report Jacques Raphael, Michelle Lui, Laura Jimenez-Juan, Suneil Khanna, Sunil Verma

Primary pulmonary hepatoid adenocarcinoma: A case report

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful.

Spontaneous regression of small cell lung cancer

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Quiz page answers january 2004

Fungating malignant phyllodes tumor

Pancreatic Cancer—Could It Be that Simple

Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation Diogo D.G. Bugano, Neda Kalhor,

Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion Eckart Laack, MD, Ronald.

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M–Mutant Leptomeningeal Lung Adenocarcinoma Christine Cordova, MD, Andrew S. Chi,

Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Metastatic Angiosarcoma Arising From the Right Atrium: Unusual Presentation and Excellent Response to Treatment in a Young Patient Martin Fehr, MD, Max.

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise Chad G. Rusthoven, MD, Brian.

Zheng Wang, Xing-Mao Zhang, Jun-Jie Hu, Zhi-Xiang Zhou

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

Erosion of lumbar vertebral bodies from a chronic contained rupture of an abdominal aortic pseudoaneurysm W. Andrew Oldenburg, MD, Tariq Almerey, MD

Intramedullary Reactive Fibrosis as Mimic of Prostate Cancer Bone Metastasis on 11C- Choline Positron Emission and Computed Tomography Tyler Trump, BS,

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Activity of Gefitinib in a Non–Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations Alessandro Morabito, MD, Raffaele Costanzo,

Bilateral Subdural Hematoma Associated with Central Nervous System Metastases from Lung Cancer Akito Hata, MD, Shiro Fujita, MD, PhD, Nobuyuki Katakami,

MRI as an Alternative to CT-Guided Biopsy of Adrenal Masses in Patients With Lung Cancer Lawrence H Schwartz, Michelle S Ginsberg, Michael E Burt, Karen.

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement Denis Maillet, MD, Isabelle Martel-Lafay,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Joaquim Bellmunt European Urology Supplements

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

David Garfield, MD Journal of Thoracic Oncology

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib Tatsuya.

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report Katarzyna Dziadziuszko, MD, Edyta Szurowska, MD, PhD, Joanna.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos, M. Mark, M. Früh, R. Cathomas Cancer Treatment and Research Communications Volume 2, Issue 1, Pages 4-7 (January 2014) DOI: 10.1016/j.ctrc.2014.03.001 Copyright © 2014 The Authors Terms and Conditions

Figure 1 Magnetic resonance imaging (MRI) and computed tomography (CT) scans showing the process of brain metastases: at initial diagnosis (A), after first line therapy with whole brain radiation therapy (WBRT) and erlotinib (B), at first relapse (C), after repeated WBRT and continued erlotinib (D), at second relapse (E), after therapy with gefitinib (F). Cancer Treatment and Research Communications 2014 2, 4-7DOI: (10.1016/j.ctrc.2014.03.001) Copyright © 2014 The Authors Terms and Conditions